We performed a NMA using the statistical method of the frequentist approach [102] to evaluate four phase III trials [100,103,104,105] including 1305 patients for PFS to examine first-line treatment of NSCLC with EGFR-activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.